title: Teneligliptin in management of type 2 diabetes mellitus.
abstract: Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. Teneligliptin has been recently available in Japan (Teneria(®)), Argentina (Teneglucon(®)), and India (Tenepure; Teneza) at relatively affordable price. This is a positive step toward the management of T2DM in developing countries, where the cost of medicine is out-of-pocket expenditure and is a limiting factor for health care. This review evaluates the efficacy and safety of teneligliptin in the management of T2DM. Teneligliptin has been systematically evaluated in T2DM as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies. These studies have reported a reduction in HbA1c of 0.8%-0.9% within 12 weeks of therapy. Two 52-week studies reported sustained improvement in glycemic control with teneligliptin. Teneligliptin has been found to be well tolerated, and the safety profile is similar to other dipeptidyl peptidase 4 inhibitors. Hypoglycemia and constipation are the main adverse events. Teneligliptin can be administered safely to patients with mild, moderate, or severe renal impairment or end-stage renal disease without dose adjustment. Similarly, it can be used in patients with mild-to-moderate hepatic impairment. Teneligliptin is effective and well tolerated and may have an important role in the management of T2DM.
authors: Diabetes, Thyroid and Endocrine Centre, Galaxy Speciality Centre, Jaipur.
authors: Surendra Kumar
authors: SK
authors: Sharma
authors: Aruna Diabetes Centre, Chennai.
authors: A
authors: A
authors: Panneerselvam
authors: Fortis Hospital, Sector 62, Phase VIII, Mohali.
authors: K P
authors: KP
authors: Singh
authors: Kokilaben Dhirubhai Ambani Hospital, Andheri (W), Mumbai.
authors: Girish
authors: G
authors: Parmar
authors: Dr Gadge's Diabetes Care Centre, Mumbai.
authors: Pradeep
authors: P
authors: Gadge
authors: Unichem Laboratories Ltd, Jogeshwari (W), Mumbai, India.
authors: Onkar C
authors: OC
authors: Swami
keywords: India; diabetes mellitus; dipeptidyl peptidase 4 inhibitor; newer DPP-4 inhibitor; teneligliptin